December 23, 2024

Hyperglycemia Confirmed as Dominant Risk Factor for Retinopathy

Higher body mass index and hypertension should also be managed to reduce risk.

Conexiant

December 23, 2024

Pathogenesis and Future Immunotherapy Treatment Directions for Uveitis, DR, AMD, and Graves’ Ophthalmopathy

An overview of the roles of immune cells, cytokines, and signaling pathways for these diseases.

Conexiant

December 20, 2024

Empagliflozin Reduces Risk of Diabetic Retinopathy Progression

Investigators found a 22% reduced risk of progression in patients with preexisting NPDR.

Conexiant

December 20, 2024

Workplace Discrimination in Ophthalmology

“Your husband also works, so you’re the second income.’”

Conexiant

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

December 03, 2024

Novel Eye Perfusion Model Advances Retinal Disease Research

Innovative perfusion techniques recreate physiological conditions in the retina, offering a powerful tool for studying blindness and eye diseases.

Conexiant

December 02, 2024

2024 Vitamin D Guidelines: A Critical Review

"If the pharmaceutical industry had developed a single drug capable of reducing cancer mortality by 25%, autoimmune disorders by 39%, and COVID-19 infection rates by 74%, it would be heralded as a miracle drug."

Conexiant

June 10, 2024

Melatonin May Reduce Age-related Macular Degeneration Risk

Melatonin use is associated with a reduced risk of developing and progressing age-related macular degeneration.

Conexiant

June 06, 2024

U.S. FDA Halts Biomea's Diabetes Trial

Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.

Reuters